Breast Cancer Tumor Stroma: Cellular Components, Phenotypic Heterogeneity, Intercellular Communication, Prognostic Implications and Therapeutic Opportunities

Balkwill, 2012, The tumor microenvironment at a glance, J. Cell Sci., 125, 5591, 10.1242/jcs.116392

Anderberg, 2009, On the origin of cancer-associated fibroblasts, Cell Cycle, 8, 1461, 10.4161/cc.8.10.8557

Zhu, 2007, Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells, Proc. Natl. Acad. Sci. USA, 104, 11754, 10.1073/pnas.0703040104

Nakagawa, 2004, Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles, Oncogene, 23, 7366, 10.1038/sj.onc.1208013

Walter, 2010, Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts, Clin. Cancer Res., 16, 1781, 10.1158/1078-0432.CCR-09-1913

Glentis, 2017, Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane, Nat. Commun., 8, 924, 10.1038/s41467-017-00985-8

Koontongkaew, 2013, The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas, J. Cancer, 4, 66, 10.7150/jca.5112

Madar, 2013, ‘Cancer associated fibroblasts’—More than meets the eye, Trends Mol. Med., 19, 447, 10.1016/j.molmed.2013.05.004

Erez, 2010, Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner, Cancer Cell, 17, 135, 10.1016/j.ccr.2009.12.041

Kalluri, 2006, Fibroblasts in cancer, Nat. Rev. Cancer, 6, 392, 10.1038/nrc1877

Allen, 2011, Jekyll and Hyde: The role of the microenvironment on the progression of cancer, J. Pathol., 223, 162, 10.1002/path.2803

Mao, 2013, Stromal cells in tumor microenvironment and breast cancer, Cancer Metastasis Rev., 32, 303, 10.1007/s10555-012-9415-3

Gonzalez, 2016, Gene expression profile of normal and cancer-associated fibroblasts according to intratumoral inflammatory cells phenotype from breast cancer tissue, Mol. Carcinog., 55, 1489, 10.1002/mc.22403

Cohen, 2009, Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1, Carcinogenesis, 30, 698, 10.1093/carcin/bgp043

Protti, 2012, Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer, Oncoimmunology, 1, 89, 10.4161/onci.1.1.17939

Straussman, 2012, Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, 487, 500, 10.1038/nature11183

Sun, X., Mao, Y., Wang, J., Zu, L., Hao, M., Cheng, G., Qu, Q., Cui, D., Keller, E.T., and Chen, X. (2014). IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene.

Eichten, 2006, Paradoxical roles of the immune system during cancer development, Nat. Rev. Cancer, 6, 24, 10.1038/nrc1782

Lin, 2004, Role of infiltrated leucocytes in tumour growth and spread, Br. J. Cancer, 90, 2053, 10.1038/sj.bjc.6601705

Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322

Daniel, 2005, CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer, Cancer Res., 65, 2018, 10.1158/0008-5472.CAN-04-3444

Sica, 2007, Altered macrophage differentiation and immune dysfunction in tumor development, J. Clin. Investig., 117, 1155, 10.1172/JCI31422

Balkwill, 2004, Cancer and the chemokine network, Nat. Rev. Cancer, 4, 540, 10.1038/nrc1388

Stamenkovic, 2008, Tumor-host interactions: The role of inflammation, Histochem. Cell Biol., 130, 1079, 10.1007/s00418-008-0527-3

Bingle, 2002, The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies, J. Pathol., 196, 254, 10.1002/path.1027

Lewis, 2006, Distinct role of macrophages in different tumor microenvironments, Cancer Res., 66, 605, 10.1158/0008-5472.CAN-05-4005

Alexe, 2007, High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates, Cancer Res., 67, 10669, 10.1158/0008-5472.CAN-07-0539

Arnould, 2006, Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?, Br. J. Cancer, 94, 259, 10.1038/sj.bjc.6602930

Bates, 2006, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse, J. Clin. Oncol., 24, 5373, 10.1200/JCO.2006.05.9584

Desmedt, 2008, Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes, Clin. Cancer Res., 14, 5158, 10.1158/1078-0432.CCR-07-4756

Rody, 2009, T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers, Breast Cancer Res., 11, R15, 10.1186/bcr2234

Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J. Clin. Oncol., 28, 105, 10.1200/JCO.2009.23.7370

Lofdahl, 2012, Inflammatory cells in node-negative breast cancer, Acta Oncol., 51, 680, 10.3109/0284186X.2011.652737

Mahmoud, 2011, An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer, Breast Cancer Res. Treat., 127, 99, 10.1007/s10549-010-0987-8

Mahmoud, 2012, The prognostic significance of B lymphocytes in invasive carcinoma of the breast, Breast Cancer Res. Treat., 132, 545, 10.1007/s10549-011-1620-1

Takenaka, 2013, FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis, Mol. Clin. Oncol., 1, 625, 10.3892/mco.2013.107

Ibrahim, 2014, The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: A meta-analysis, Breast Cancer Res. Treat., 148, 467, 10.1007/s10549-014-3185-2

Yeong, 2017, Higher densities of Foxp3(+) regulatory T cells are associated with better prognosis in triple-negative breast cancer, Breast Cancer Res. Treat., 163, 21, 10.1007/s10549-017-4161-4

Eiro, N., Pidal, I., Fernandez-Garcia, B., Junquera, S., Lamelas, M.L., del Casar, J.M., Gonzalez, L.O., Lopez-Muniz, A., and Vizoso, F.J. (2012). Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS ONE, 7.

Webb, 2018, Immune checkpoint inhibitors in cancer therapy, J. Biomed. Res., 32, 317, 10.7555/JBR.31.20160168

Butler, 2010, Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors, Nat. Rev. Cancer, 10, 138, 10.1038/nrc2791

Butler, 2012, Generation of a vascular niche for studying stem cell homeostasis, Methods Mol. Biol., 904, 221, 10.1007/978-1-61779-943-3_18

Ghajar, 2013, The perivascular niche regulates breast tumour dormancy, Nat. Cell Biol., 15, 807, 10.1038/ncb2767

Ghiabi, P., Jiang, J., Pasquier, J., Maleki, M., Abu-Kaoud, N., Rafii, S., and Rafii, A. (2014). Endothelial cells provide a notch-dependent pro-tumoral niche for enhancing breast cancer survival, stemness and pro-metastatic properties. PLoS ONE, 9.

Folkman, 1989, Induction of angiogenesis during the transition from hyperplasia to neoplasia, Nature, 339, 58, 10.1038/339058a0

Hida, 2013, Heterogeneity of tumor endothelial cells, Cancer Sci., 104, 1391, 10.1111/cas.12251

Lazennec, 2008, Concise review: Adult multipotent stromal cells and cancer: Risk or benefit?, Stem Cells, 26, 1387, 10.1634/stemcells.2007-1006

Dominici, 2006, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, 8, 315, 10.1080/14653240600855905

Timmers, 2007, Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium, Stem Cell Res., 1, 129, 10.1016/j.scr.2008.02.002

Ridge, 2017, Mesenchymal stem cells: Key players in cancer progression, Mol. Cancer, 16, 31, 10.1186/s12943-017-0597-8

Lazennec, 2016, Recent discoveries concerning the tumor—Mesenchymal stem cell interactions, Biochim. Biophys. Acta, 1866, 290

Hass, 2012, Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment, Cell Commun. Signal, 10, 26, 10.1186/1478-811X-10-26

Karnoub, 2010, Mesenchymal stem cells in the pathogenesis and therapy of breast cancer, J. Mammary Gland Biol. Neoplasia, 15, 399, 10.1007/s10911-010-9196-7

Anthony, 2014, Regulation of hematopoietic stem cells by bone marrow stromal cells, Trends Immunol., 35, 32, 10.1016/j.it.2013.10.002

Sanchez, 2016, Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche, Oncotarget, 7, 3993, 10.18632/oncotarget.6540

Zhu, 2012, Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo, Cancer Lett., 315, 28, 10.1016/j.canlet.2011.10.002

Melzer, 2016, Interaction of MSC with tumor cells, Cell Commun. Signal, 14, 20, 10.1186/s12964-016-0143-0

Szczepanski, 2011, Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1, Haematologica, 96, 1302, 10.3324/haematol.2010.039743

Mandel, 2013, Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo, Stem Cells Dev., 22, 3114, 10.1089/scd.2013.0249

Syn, 2016, Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance, Trends Pharmacol. Sci., 37, 606, 10.1016/j.tips.2016.04.006

Shi, 2016, Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression, Am. J. Cancer Res., 6, 459

Meng, 2007, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer, Gastroenterology, 133, 647, 10.1053/j.gastro.2007.05.022

Provenzano, 2009, Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage, Oncogene, 28, 4326, 10.1038/onc.2009.299

Narayanan, 2016, Hijacking the Cellular Mail: Exosome Mediated Differentiation of Mesenchymal Stem Cells, Stem Cells Int., 2016, 3808674, 10.1155/2016/3808674

Cho, 2012, Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells, Int. J. Oncol., 40, 130

Zhang, 2014, Mesenchymal stem cells secrete immunologically active exosomes, Stem Cells Dev., 23, 1233, 10.1089/scd.2013.0479

Mokarizadeh, 2012, Microvesicles derived from mesenchymal stem cells: Potent organelles for induction of tolerogenic signaling, Immunol. Lett., 147, 47, 10.1016/j.imlet.2012.06.001

Luciano, 2015, Immunoregulatory Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles on T Lymphocytes, Cell Transplant., 24, 2615, 10.3727/096368915X687543

Phinney, 2015, Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs, Nat. Commun., 6, 8472, 10.1038/ncomms9472

Conforti, 2014, Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro, Stem Cells Dev., 23, 2591, 10.1089/scd.2014.0091

Chen, 2016, Immunomodulatory effects of mesenchymal stromal cells-derived exosome, Immunol. Res., 64, 831, 10.1007/s12026-016-8798-6

Amarnath, 2015, Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo, Stem Cells, 33, 1200, 10.1002/stem.1934

Ono, 2014, Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells, Sci. Signal., 7, ra63, 10.1126/scisignal.2005231

Ohyashiki, 2016, Exosomes promote bone marrow angiogenesis in hematologic neoplasia: The role of hypoxia, Curr. Opin. Hematol., 23, 268, 10.1097/MOH.0000000000000235

Allavena, 2008, The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance, Immunol. Rev., 222, 155, 10.1111/j.1600-065X.2008.00607.x

Chen, 2013, Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines, J. Immunol., 190, 5065, 10.4049/jimmunol.1202775

Waterman, R.S., Henkle, S.L., and Betancourt, A.M. (2012). Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS ONE, 7.

Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat. Rev. Cancer, 2, 161, 10.1038/nrc745

Noe, 2001, Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1, J. Cell Sci., 114, 111, 10.1242/jcs.114.1.111

Rundhaug, 2005, Matrix metalloproteinases and angiogenesis, J. Cell. Mol. Med., 9, 267, 10.1111/j.1582-4934.2005.tb00355.x

Jiang, 2002, Complex roles of tissue inhibitors of metalloproteinases in cancer, Oncogene, 21, 2245, 10.1038/sj.onc.1205291

Wurtz, 2005, Tissue inhibitor of metalloproteinases-1 in breast cancer, Endocr. Relat. Cancer, 12, 215, 10.1677/erc.1.00719

Jiang, 2005, siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line, J. Cell. Physiol., 202, 723, 10.1002/jcp.20162

Jones, 1997, Control of matrix metalloproteinase activity in cancer, J. Pathol., 183, 377, 10.1002/(SICI)1096-9896(199712)183:4<377::AID-PATH951>3.0.CO;2-R

Nakopoulou, 2002, Stromelysin-3 protein expression in invasive breast cancer: Relation to proliferation, cell survival and patients’ outcome, Mod. Pathol., 15, 1154, 10.1097/01.MP.0000037317.84782.CD

Vizoso, 2007, Study of matrix metalloproteinases and their inhibitors in breast cancer, Br. J. Cancer, 96, 903, 10.1038/sj.bjc.6603666

Eiro, 2015, A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer, Oncoimmunology, 4, e992222, 10.4161/2162402X.2014.992222

Eiró, N., Fernandez-Garcia, B., González, L.O., and Vizoso, F.J. (2013). Clinical Relevance of Matrix Metalloproteases and their Inhibitors in Breast Cancer. J. Carcinog. Mutagen., s13.

Gonzalez, 2010, Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas, Histopathology, 57, 862, 10.1111/j.1365-2559.2010.03723.x

Gonzalez, 2009, Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas, Breast Cancer Res. Treat., 116, 39, 10.1007/s10549-009-0351-z

Gonzalez, 2009, Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma, Hum. Pathol., 40, 1224, 10.1016/j.humpath.2008.12.022

Gonzalez, 2010, Expression of metalloproteases and their inhibitors in different histological types of breast cancer, J. Cancer Res. Clin. Oncol., 136, 811, 10.1007/s00432-009-0721-2

Eiro, N., Gonzalez, L., Gonzalez, L.O., Fernandez-Garcia, B., Lamelas, M.L., Marin, L., Gonzalez-Reyes, S., del Casar, J.M., and Vizoso, F.J. (2012). Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS ONE, 7.

Eiro, 2013, Cytokines related to MMP-11 expression by inflammatory cells and breast cancer metastasis, Oncoimmunology, 2, e24010, 10.4161/onci.24010

Manicone, 2008, Matrix metalloproteinases as modulators of inflammation, Semin. Cell Dev. Biol., 19, 34, 10.1016/j.semcdb.2007.07.003

Cid, 2016, Expression and Clinical Significance of Metalloproteases and Their Inhibitors by Endothelial Cells From Invasive Breast Carcinomas, Clin. Breast Cancer, 16, e83, 10.1016/j.clbc.2016.05.007

Qi, 2003, A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2, Nat. Med., 9, 407, 10.1038/nm846

Kim, 2006, TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis, Oncogene, 25, 650, 10.1038/sj.onc.1209104

Qi, 2015, Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism, Apoptosis, 20, 523, 10.1007/s10495-014-1076-y

Zamarron, 2011, Dual roles of immune cells and their factors in cancer development and progression, Int. J. Biol. Sci., 7, 651, 10.7150/ijbs.7.651

Landskron, 2014, Chronic inflammation and cytokines in the tumor microenvironment, J. Immunol. Res., 2014, 149185, 10.1155/2014/149185

Castro, 2015, The role of cytokines in breast cancer development and progression, J. Interferon Cytokine Res., 35, 1, 10.1089/jir.2014.0026

Lin, 2015, Interleukin-6 as a prognostic marker for breast cancer: A meta-analysis, Tumori, 101, 535, 10.5301/tj.5000357

Tripsianis, 2014, Coexpression of IL-6 and TNF-alpha: Prognostic significance on breast cancer outcome, Neoplasma, 61, 205, 10.4149/neo_2014_026

Eiro, 2016, Prognostic significance of inflammatory factors expression by stroma from breast carcinomas, Carcinogenesis, 37, 768, 10.1093/carcin/bgw062

Hamidullah, 2012, Role of interleukin-10 in breast cancer, Breast Cancer Res. Treat., 133, 11, 10.1007/s10549-011-1855-x

Murugaiyan, 2009, Protumor vs antitumor functions of IL-17, J. Immunol., 183, 4169, 10.4049/jimmunol.0901017

Muranski, 2009, T helper 17 cells promote cytotoxic T cell activation in tumor immunity, Immunity, 31, 787, 10.1016/j.immuni.2009.09.014

Karczewska, 2000, Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma, Cancer, 88, 2061, 10.1002/(SICI)1097-0142(20000501)88:9<2061::AID-CNCR12>3.0.CO;2-O

Benchetrit, 2002, Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism, Blood, 99, 2114, 10.1182/blood.V99.6.2114

Kawai, 2006, TLR signaling, Cell Death Differ., 13, 816, 10.1038/sj.cdd.4401850

Sato, 2009, Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment, Cancer Microenviron., 2, 205, 10.1007/s12307-009-0022-y

Huang, 2008, TLR signaling by tumor and immune cells: A double-edged sword, Oncogene, 27, 218, 10.1038/sj.onc.1210904

Medzhitov, 2008, Role of toll-like receptors in tissue repair and tumorigenesis, Biochemistry, 73, 555

Gonzalez-Reyes, S., Marin, L., Gonzalez, L., Gonzalez, L.O., del Casar, J.M., Lamelas, M.L., Gonzalez-Quintana, J.M., and Vizoso, F.J. (2010). Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer, 10.

Murad, 2007, CPG-7909 (PF-3512676, ProMune): Toll-like receptor-9 agonist in cancer therapy, Expert Opin. Biol. Ther., 7, 1257, 10.1517/14712598.7.8.1257

Sagiv-Barfi, I., Czerwinski, D.K., Levy, S., Alam, I.S., Mayer, A.T., Gambhir, S.S., and Levy, R. (2018). Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl. Med., 10.

Lambert, 2012, Integrin signaling in mammary epithelial cells and breast cancer, ISRN Oncol., 2012, 493283

Campbell, I.D., and Humphries, M.J. (2011). Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol., 3.

Mousa, 2008, Cell adhesion molecules: Potential therapeutic & diagnostic implications, Mol. Biotechnol., 38, 33, 10.1007/s12033-007-0072-7

Calderwood, 2013, Talins and kindlins: Partners in integrin-mediated adhesion, Nat. Rev. Mol. Cell Biol., 14, 503, 10.1038/nrm3624

Desgrosellier, 2010, Integrins in cancer: Biological implications and therapeutic opportunities, Nat. Rev. Cancer, 10, 9, 10.1038/nrc2748

Legate, 2006, ILK, PINCH and parvin: The tIPP of integrin signalling, Nat. Rev. Mol. Cell Biol., 7, 20, 10.1038/nrm1789

Hynes, 2002, Integrins: Bidirectional, allosteric signaling machines, Cell, 110, 673, 10.1016/S0092-8674(02)00971-6

Bianconi, D., Unseld, M., and Prager, G.W. (2016). Integrins in the Spotlight of Cancer. Int. J. Mol. Sci., 17.

Fassler, 2014, The integrin adhesome: From genes and proteins to human disease, Nat. Rev. Mol. Cell Biol., 15, 273, 10.1038/nrm3769

Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Yuan, 2016, Role of the tumor microenvironment in tumor progression and the clinical applications (Review), Oncol. Rep., 35, 2499, 10.3892/or.2016.4660

Derbal, 2017, Perspective on the dynamics of cancer, Theor. Biol. Med. Model., 14, 18, 10.1186/s12976-017-0066-5

Gandellini, 2015, Complexity in the tumour microenvironment: Cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types, Semin. Cancer Biol., 35, 96, 10.1016/j.semcancer.2015.08.008

Harper, 2014, Regulation of the anti-tumour immune response by cancer-associated fibroblasts, Semin. Cancer Biol., 25, 69, 10.1016/j.semcancer.2013.12.005

Popivanova, 2009, Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice, Cancer Res., 69, 7884, 10.1158/0008-5472.CAN-09-1451

Roca, 2009, CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization, J. Biol. Chem., 284, 34342, 10.1074/jbc.M109.042671

Sumimoto, 2006, The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells, J. Exp. Med., 203, 1651, 10.1084/jem.20051848

Shchors, 2006, The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta, Genes Dev., 20, 2527, 10.1101/gad.1455706

Eiro, 2018, Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis, Cell. Oncol., 41, 369, 10.1007/s13402-018-0371-y

Cocucci, 2015, Ectosomes and exosomes: Shedding the confusion between extracellular vesicles, Trends Cell Biol., 25, 364, 10.1016/j.tcb.2015.01.004

Abels, 2016, Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake, Cell. Mol. Neurobiol., 36, 301, 10.1007/s10571-016-0366-z

Boyiadzis, 2017, The emerging roles of tumor-derived exosomes in hematological malignancies, Leukemia, 31, 1259, 10.1038/leu.2017.91

Muller, 2016, Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets, Sci. Rep., 6, 20254, 10.1038/srep20254

Muller, 2017, Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms, Oncoimmunology, 6, e1261243, 10.1080/2162402X.2016.1261243

Mulcahy, L.A., Pink, R.C., and Carter, D.R. (2014). Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles, 3.

Ludwig, 2017, Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer, Clin. Cancer Res., 23, 4843, 10.1158/1078-0432.CCR-16-2819

Hong, 2016, Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer, J. Extracell. Vesicles, 5, 29289, 10.3402/jev.v5.29289

Boyiadzis, 2015, Information transfer by exosomes: A new frontier in hematologic malignancies, Blood Rev., 29, 281, 10.1016/j.blre.2015.01.004

Whiteside, 2017, Exosomes carrying immunoinhibitory proteins and their role in cancer, Clin. Exp. Immunol., 189, 259, 10.1111/cei.12974

Bassi, 2016, Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions, Sci. Rep., 6, 24120, 10.1038/srep24120

Marote, 2016, MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential, Front. Pharmacol., 7, 231, 10.3389/fphar.2016.00231

Lener, 2015, Applying extracellular vesicles based therapeutics in clinical trials—An ISEV position paper, J. Extracell. Vesicles, 4, 30087, 10.3402/jev.v4.30087

Burnstock, 2013, Purinergic signalling and cancer, Purinergic Signal., 9, 491, 10.1007/s11302-013-9372-5

Lai, 2012, Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome, Int. J. Proteom., 2012, 971907, 10.1155/2012/971907

Chen, 2010, Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs, Nucleic Acids Res., 38, 215, 10.1093/nar/gkp857

Whiteside, 2018, Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment, Semin. Immunol., 35, 69, 10.1016/j.smim.2017.12.003

Dostert, 2017, How Do Mesenchymal Stem Cells Influence or Are Influenced by Microenvironment through Extracellular Vesicles Communication?, Front. Cell Dev. Biol., 5, 6, 10.3389/fcell.2017.00006

Sharma, 2014, Bioinformatic analysis revealing association of exosomal mRNAs and proteins in epigenetic inheritance, J. Theor. Biol., 357, 143, 10.1016/j.jtbi.2014.05.019

Lindoso, 2015, Extracellular vesicles derived from renal cancer stem cells induce a pro-tumorigenic phenotype in mesenchymal stromal cells, Oncotarget, 6, 7959, 10.18632/oncotarget.3503

Seguin, 2015, Integrins and cancer: Regulators of cancer stemness, metastasis, and drug resistance, Trends Cell Biol., 25, 234, 10.1016/j.tcb.2014.12.006

Hamidi, 2016, The complexity of integrins in cancer and new scopes for therapeutic targeting, Br. J. Cancer, 115, 1017, 10.1038/bjc.2016.312

Guo, 2004, Integrin signalling during tumour progression, Nat. Rev. Mol. Cell Biol., 5, 816, 10.1038/nrm1490

Hehlgans, 2007, Signalling via integrins: Implications for cell survival and anticancer strategies, Biochim. Biophys. Acta, 1775, 163

Kuphal, 2005, Integrin signaling in malignant melanoma, Cancer Metastasis Rev., 24, 195, 10.1007/s10555-005-1572-1

Glukhova, 2013, How integrins control breast biology, Curr. Opin. Cell Biol., 25, 633, 10.1016/j.ceb.2013.06.010

Hamidi, 2018, Every step of the way: Integrins in cancer progression and metastasis, Nat. Rev. Cancer, 18, 533, 10.1038/s41568-018-0038-z

Cagnet, 2014, Signaling events mediated by alpha3beta1 integrin are essential for mammary tumorigenesis, Oncogene, 33, 4286, 10.1038/onc.2013.391

White, 2004, Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction, Cancer Cell, 6, 159, 10.1016/j.ccr.2004.06.025

Stoletov, 2010, Visualizing extravasation dynamics of metastatic tumor cells, J. Cell Sci., 123, 2332, 10.1242/jcs.069443

Zanetti, 2012, Beta 1 integrin predicts survival in breast cancer: A clinicopathological and immunohistochemical study, Diagn. Pathol., 7, 104, 10.1186/1746-1596-7-104

Jahangiri, 2014, beta1 integrin: Critical path to antiangiogenic therapy resistance and beyond, Cancer Res., 74, 3, 10.1158/0008-5472.CAN-13-1742

Sun, 2018, Prognostic value of increased integrin-beta 1 expression in solid cancers: A meta-analysis, OncoTargets Ther., 11, 1787, 10.2147/OTT.S155279

Friedrichs, 1995, High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival, Cancer Res., 55, 901

Hu, 2016, Integrin alpha6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy, Sci. Rep., 6, 33376, 10.1038/srep33376

Huck, 2010, beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression, Proc. Natl. Acad. Sci. USA, 107, 15559, 10.1073/pnas.1003034107

Ramirez, 2011, The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer, J. Clin. Investig., 121, 226, 10.1172/JCI42328

Lanzafame, 1996, Correlation of alpha 2 beta 1 integrin expression with histological type and hormonal receptor status in breast carcinomas, Pathol. Res. Pract., 192, 1031, 10.1016/S0344-0338(96)80045-8

Gonzalez, 1999, An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer, J. Pathol., 187, 523, 10.1002/(SICI)1096-9896(199904)187:5<523::AID-PATH296>3.0.CO;2-3

Petricevic, 2012, Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer, Med. Oncol., 29, 486, 10.1007/s12032-011-9885-0

Berry, 2004, Integrin expression and survival in human breast cancer, Eur. J. Surg. Oncol., 30, 484, 10.1016/j.ejso.2004.01.016

Attieh, 2017, Cancer-associated fibroblasts lead tumor invasion through integrin-beta3-dependent fibronectin assembly, J. Cell Biol., 216, 3509, 10.1083/jcb.201702033

Cavaco, A.C.M., Rezaei, M., Caliandro, M.F., Lima, A.M., Stehling, M., Dhayat, S.A., Haier, J., Brakebusch, C., and Eble, J.A. (2018). The Interaction between Laminin-332 and alpha3beta1 Integrin Determines Differentiation and Maintenance of CAFs, and Supports Invasion of Pancreatic Duct Adenocarcinoma Cells. Cancers, 11.

Erdogan, 2017, Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin, J. Cell Biol., 216, 3799, 10.1083/jcb.201704053

Pontiggia, 2012, The tumor microenvironment modulates tamoxifen resistance in breast cancer: A role for soluble stromal factors and fibronectin through beta1 integrin, Breast Cancer Res. Treat., 133, 459, 10.1007/s10549-011-1766-x

Dittmer, 2018, Long-term exposure to carcinoma-associated fibroblasts makes breast cancer cells addictive to integrin beta1, Oncotarget, 9, 22079, 10.18632/oncotarget.25183

Zhou, 2015, Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth, Nat. Cell Biol., 17, 170, 10.1038/ncb3090

Kale, 2014, Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin, Oncogene, 33, 2295, 10.1038/onc.2013.184

Yakubenko, 2000, Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin, Exp. Cell Res., 260, 73, 10.1006/excr.2000.5002

Bank, 1994, Functional role of VLA-1 (CD49A) in adhesion, cation-dependent spreading, and activation of cultured human T lymphocytes, Cell. Immunol., 156, 424, 10.1006/cimm.1994.1187

Park, 2010, Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes, Blood, 115, 1572, 10.1182/blood-2009-08-237917

Bertoni, A., Alabiso, O., Galetto, A.S., and Baldanzi, G. (2018). Integrins in T Cell Physiology. Int. J. Mol. Sci., 19.

Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, 284, 1994, 10.1126/science.284.5422.1994

Munshi, 2006, Reciprocal interactions between adhesion receptor signaling and MMP regulation, Cancer Metastasis Rev., 25, 45, 10.1007/s10555-006-7888-7

Silletti, 2001, Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo, Proc. Natl. Acad. Sci. USA, 98, 119

Rolli, 2003, Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells, Proc. Natl. Acad. Sci. USA, 100, 9482, 10.1073/pnas.1633689100

Nisato, 2005, Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: Absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical, Cancer Res., 65, 9377, 10.1158/0008-5472.CAN-05-1512

Moritz, 2018, Alternagin-C binding to alpha2beta1 integrin controls matrix metalloprotease-9 and matrix metalloprotease-2 in breast tumor cells and endothelial cells, J. Venom. Anim. Toxins Incl. Trop. Dis., 24, 13, 10.1186/s40409-018-0150-2

Bjorklund, 2004, Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion, J. Biol. Chem., 279, 29589, 10.1074/jbc.M401601200

Barkan, 2008, Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton, Cancer Res., 68, 6241, 10.1158/0008-5472.CAN-07-6849

Shibue, 2009, Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs, Proc. Natl. Acad. Sci. USA, 106, 10290, 10.1073/pnas.0904227106

Wu, 2017, Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells, Int. J. Nanomed., 12, 5069, 10.2147/IJN.S137833

Nam, 2013, beta1-Integrin via NF-kappaB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer, Breast Cancer Res., 15, R60, 10.1186/bcr3454

Peinado, 2017, Pre-metastatic niches: Organ-specific homes for metastases, Nat. Rev. Cancer, 17, 302, 10.1038/nrc.2017.6

Paget, 1989, The distribution of secondary growths in cancer of the breast. 1889, Cancer Metastasis Rev., 8, 98

Prada, I., and Meldolesi, J. (2016). Binding and Fusion of Extracellular Vesicles to the Plasma Membrane of Their Cell Targets. Int. J. Mol. Sci., 17.

Hoshino, 2015, Tumour exosome integrins determine organotropic metastasis, Nature, 527, 329, 10.1038/nature15756

Alderton, 2015, Metastasis: Directions to metastatic sites, Nat. Rev. Cancer, 15, 696, 10.1038/nrc4046

Paolillo, M., and Schinelli, S. (2017). Integrins and Exosomes, a Dangerous Liaison in Cancer Progression. Cancers, 9.

Kristensen, 2014, Anti-vascular endothelial growth factor therapy in breast cancer, Int. J. Mol. Sci., 15, 23024, 10.3390/ijms151223024

Sun, 2015, Translational horizons in the tumor microenvironment: Harnessing breakthroughs and targeting cures, Med. Res. Rev., 35, 408, 10.1002/med.21338

Slany, 2015, Targeting breast cancer-associated fibroblasts to improve anti-cancer therapy, Breast, 24, 532, 10.1016/j.breast.2015.06.009

Correia, 2012, The tumor microenvironment is a dominant force in multidrug resistance, Drug Resist. Updat., 15, 39, 10.1016/j.drup.2012.01.006

Kerbel, 1997, A cancer therapy resistant to resistance, Nature, 390, 335, 10.1038/36978

Tuder, 2012, Lactate, a novel trigger of transforming growth factor-beta activation in idiopathic pulmonary fibrosis, Am. J. Respir. Crit. Care Med., 186, 701, 10.1164/rccm.201208-1491ED

Zhang, 2013, Tumor stroma as targets for cancer therapy, Pharmacol. Ther., 137, 200, 10.1016/j.pharmthera.2012.10.003

Khan, 2018, Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy, Curr. Drug Targets, 19, 1573, 10.2174/1389450119666180219124439

Dorff, 2010, Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer, Clin. Cancer Res., 16, 3028, 10.1158/1078-0432.CCR-09-3122

Alas, 2001, Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis, Clin. Cancer Res., 7, 709

Migali, 2016, Strategies to modulate the immune system in breast cancer: Checkpoint inhibitors and beyond, Ther. Adv. Med. Oncol., 8, 360, 10.1177/1758834016658423

Maffey, 2017, Mesenchymal stem cells from tumor microenvironment favour breast cancer stem cell proliferation, cancerogenic and metastatic potential, via ionotropic purinergic signalling, Sci. Rep., 7, 13162, 10.1038/s41598-017-13460-7

Klopp, 2011, Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth?, Stem Cells, 29, 11, 10.1002/stem.559

Zismanov, 2016, Secretome of human bone marrow mesenchymal stem cells: An emerging player in lung cancer progression and mechanisms of translation initiation, Tumor Biol., 37, 4755, 10.1007/s13277-015-4304-3

Marcus, 2016, Mesenchymal stem cells secretomes’ affect multiple myeloma translation initiation, Cell. Signal., 28, 620, 10.1016/j.cellsig.2016.03.003

Onzi, 2016, Analysis of the safety of mesenchymal stromal cells secretome for glioblastoma treatment, Cytotherapy, 18, 828, 10.1016/j.jcyt.2016.03.299

Eiro, 2014, Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells, Oncotarget, 5, 10692, 10.18632/oncotarget.2530

Karnoub, 2007, Mesenchymal stem cells within tumour stroma promote breast cancer metastasis, Nature, 449, 557, 10.1038/nature06188

Muehlberg, 2009, Tissue-resident stem cells promote breast cancer growth and metastasis, Carcinogenesis, 30, 589, 10.1093/carcin/bgp036

Galie, 2008, Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice, Oncogene, 27, 2542, 10.1038/sj.onc.1210920

Vizoso, F.J., Eiro, N., Cid, S., Schneider, J., and Perez-Fernandez, R. (2017). Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. Int. J. Mol. Sci., 18.

Schneider, 2016, Human Uterine Cervical Stromal Stem Cells (hUCESCs): Why and How they Exert their Antitumor Activity, Cancer Genom. Proteom., 13, 331

Curley, 1999, Integrin antagonists, Cell Mol. Life Sci., 56, 427, 10.1007/s000180050443

Raab-Westphal, S., Marshall, J.F., and Goodman, S.L. (2017). Integrins as Therapeutic Targets: Successes and Cancers. Cancers, 9.